This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 28 open trials.
In 123 locations
What is a Clinical Trial?
There are currently 28 open trials
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Using diffusion weighted MRI to measure myeloma disease burden and bone loss (LOOMIS)
- Daratumumab in combination with standard myeloma treatment
- Exercise in transplant eligible myeloma patients (PERCEPT)
- Daratumumab with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients
- Daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed AL amyloidosis
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Effects of an exercise programme on smouldering myeloma and MGUS
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- GSK2857916 in patients who have failed prior treatment with an anti-CD38 antibody (DREAMM 2)
- AZD4573 in relapsed or refractory myeloma
- Daratumumab vs. monitoring in high risk smouldering myeloma
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Observational study of presentation, treatment and outcomes in myeloma patients (INSIGHT-MM)
- Observational evaluation of myeloma patients (PREAMBLE)
- Image guided theranostics in myeloma (iTIMM)
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- Myeloma XII (ACCoRd)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK525762 trial
Trial Title:
bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
Treatments:
bb2121 (bb2121 CAR-T cells)
Myeloma stage:
Relapsed, Refractory, High risk myeloma
Trial phase:
II
Summary:
This trial is investigating whether bb2121, a type of treatment known as chimeric antigen receptor T cell (CAR T Cell) therapy, is safe and effective for the treatment of relapsed/refractory and high-risk myeloma patients.
Locations:
King's College Hospital, London
Who can enter the study?:
- Relapsed and/or refractory myeloma patients who have had at least three previous lines of treatment.
- Relapsed myeloma patients who have have had one previous line of treatment who are classed as high risk due to stage III status and early relapse (< 18 months).
What's involved?:
Prior to treatment patients undergo leukapheresis (T cell harvest). The harvested T cells are then modified to become the bb2121 treatment.
Patients will then receive the bb2121 treatment by intravenous infusion.
Patients are required to attend outpatient clinics for regular check-ups and tests.
Clinical Information
(for Medical Professionals):
This trial is a multi-cohort, open-label, multicenter Phase II trial to evaluate the efficacy and safety of bb2121 in patients with relapsed/refractory myeloma who have either received three prior lines of treatment or are high risk and have relapsed early after one prior line of treatment.
For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk